抄録
Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.
本文言語 | 英語 |
---|---|
ページ(範囲) | 2803-2808 |
ページ数 | 6 |
ジャーナル | Internal Medicine |
巻 | 58 |
号 | 19 |
DOI | |
出版ステータス | 出版済み - 2019 |
外部発表 | はい |
All Science Journal Classification (ASJC) codes
- 内科学